Skip to content
Review Open access

RSV Disease Burden in Adults in Emerging Market Countries, a Systematic Review and Modelling Analysis

Nov 2026 · Open Forum Infectious Diseases · 0 citations

TL;DR

The estimated incidence and proportion positive of RSV disease in EMC is substantially lower than HIC, and narrow case definitions requiring fever, less sensitive testing such as direct fluorescent antibody testing, reduced healthcare access, and incomplete surveillance may be contributing to these lower estimates.

Abstract

Most previous studies on adult respiratory syncytial virus (RSV) burden focus on high-income settings (HIC). With the recent approval of RSV vaccines for adults, extending epidemiological understanding to emerging market countries (EMC) is critical for informing prevention strategies. We aimed to characterize the burden of RSV among adults ≥18 years in EMC. We conducted a systematic review (PROSEPRO: CRD420251137828) to identify studies reporting estimates of RSV burden from any care setting in adults>18 years in EMC. For each individual study included, we followed a two-step statistical approach to adjust for RSV case under-ascertainment related to the use of clinical specimen and diagnostic test. Random-effects meta-analysis was conducted to estimate RSV incidence rate, proportion positive, hospitalisation, and mortality burden. We included 70 studies of which the majority were from China (30/70) and PCR was the predominant diagnostic method (59/70). Adjusted RSV disease incidence rate (approximately 2.5 times higher than unadjusted) ranged from 2,544 (95% CI 1,352-4,787) per 100,000 in adults aged 18-49 years to 2,392 (1,618-3,534) in adults ≥65 years after accounting for clinical sampling and diagnostic testing. Adjusted hospitalisation rates increased with age, from 20 (8-51) per 100,000 in 18-49 years to 74 (3-2,027) in adults ≥65 years, representing an approximate 2.5-fold increase after adjustment. The adjusted RSV proportion positive was relatively stable, ranging from 1.8% (0.4-8.5) to 9.7% (6.3-14.6), regardless of settings or clinical case definitions. The unadjusted in-hospital case fatality ratio (hCFR) was 6.0% (2.9-11.9) in adults ≥65 years vs 3.1 (2.0-5.0) in those 18-49 years. Among hospitalized RSV-positive adults, 95.8% (84.2-99.0) had at least one comorbidity, most commonly hypertension, diabetes, and COPD. The estimated incidence and proportion positive of RSV disease in EMC is substantially lower than HIC. Narrow case definitions requiring fever, less sensitive testing such as direct fluorescent antibody testing, reduced healthcare access, and incomplete surveillance may be contributing to these lower estimates. In-hospital CFR are comparable to or higher than in HIC.

Read PDF

Similar papers

Monitoring RSV in the era of immunization

It is shown that RSV causes substantial burden in primary care and emergency departments, particularly among infants, but that reported incidence estimates vary widely due to differences in study design, case definitions, age groups and testing practices, and by applying a multilevel meta-analysis, this thesis generate...

Susanne Heemskerk · 0 citations
Review Open access Sep 2026

Economic Value and Cost-Effectiveness of Respiratory Syncytial Virus Vaccination in Adults: A Systematic Review

Background: Respiratory syncytial virus (RSV) is a major cause of acute respiratory infections among older adults and individuals with chronic medical conditions. Recently developed RSV vaccines have demonstrated clinical efficacy, but their economic value remains unclear across different healthcare settings and target...

Lukman Aryoseto, H. A. Haq, M. Madani et al. · 0 citations
Review Open access Sep 2026

Maternal RSV vaccination: clinical efficacy, safety, and global policy considerations: a systematic review

ABSTRACT Background Respiratory syncytial virus (RSV) is among the leading causes of lower respiratory tract illness in newborns worldwide. This study reviews evidence on the efficacy and safety of maternal RSV vaccination. Methods PROSPERO registered this PRISMA-compliant systematic review (CRD42024566335). Keywords a...

Khawla Abu Hammour, Qusai Manaseer, Murad Dweik et al. · 0 citations
Open access Sep 2026

Modeling the potential clinical and economic impact of clesrovimab for the prevention of RSV in infants in England and Wales

Background Respiratory syncytial virus (RSV) infects nearly all children under two years, causing mild lower respiratory tract infections (LRTIs) although serious disease, mortality and long-term recurrent wheezing can also occur. Objectives This study evaluates the health and economic impact of various RSV prevention...

K. Kura, C. Burgess, Ian R. Matthews et al. · 0 citations
Review Open access Nov 2026

Respiratory syncytial virus (RSV) vaccine recommendations for adults: a review of available global, regional, and country level recommendations.

INTRODUCTION Respiratory syncytial virus (RSV) can cause serious disease in older adults (OAs), particularly those with underlying medical conditions. It can lead to acute respiratory illness and lower respiratory tract infections in adults ≥60 years and at increased risk groups. RSV morbidity, mortality, and health ca...

Otávio Cintra, Abhay Phansalkar, M. Laucho-Contreras et al. · 1 citation

From Evidence to Implementation

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections in young children. In 2019, RSV was estimated to cause approximately 33 million acute lower respiratory infections, 3.6 million hospitalisations and more than 101,000 deaths among children under five years of age, with more than...

N. Rave · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.